Rapiblyk™ Billing Codes

The reimbursement information and codes contained in this document are publicly available from third-party sources and are provided for informational purposes only. These codes are not an all-inclusive list and are not intended for, and do not constitute legal, reimbursement, or business advice. The information contained herein represents no statement, promise, or guarantee by AOP Health concerning levels of reimbursement, payment, or charge. Similarly, all codes are supplied for informational purposes only and represent no statement, promise, or guarantee by AOP Health that these codes will be appropriate or that reimbursement will be made. It is the health care provider’s responsibility to accurately report the patient diagnosis, the services provided, and the procedures performed, consistent with the payers’ guidelines. If providers have questions about coverage, coding, or payment, providers should consult the specific payers. The Center for Medicare and Medicaid Services (CMS) website is available at https://www.cms.gov/.

DRG-Bundle

Multiple DRGs may be applicable depending on specific clinical context

10 Digit NDC	84381-110-01
11 Digit NDC	84381-0110-01

DRG Code	Patient Cohort
177	Respiratory infections and inflammations with mcc
189	Pulmonary edema and respiratory failure
193	Simple pneumonia and pleurisy with mcc
314	Other circulatory system diagnoses with mcc
698	Other kidney and urinary tract diagnoses with mcc
853	Infectious and parasitic diseases with O.R. Procedures with mcc
854	Infectious and parasitic diseases with O.R. Procedures with cc
870	Septicemia or severe sepsis with mv >96 hours
871	Septicemia or severe sepsis without mv >96 hours with mcc
872	Septicemia or severe sepsis without mv >96 hours without mcc
193	Simple pneumonia and pleurisy with mcc
246	Percutaneous cardiovascular procedures with drug-eluting stent with mcc or 4+ arteries or stents
280	Acute myocardial infarction, discharged alive with mcc
286	Circulatory disorders except AMI, with cardiac catheterization with mcc
291	Heart failure and shock with mcc
292	Heart failure and shock with cc
293	Heart failure and shock without cc/mcc
308	Cardiac arrhythmia and conduction disorders with mcc
309	Cardiac arrhythmia and conduction disorders with cc
310	Cardiac arrhythmia and conduction disorders without cc/mcc
216	Cardiac valve and other major cardiothoracic procedures with cardiac catheterization with mcc
219	Cardiac valve and other major cardiothoracic procedures without cardiac catheterization with mcc
220	Cardiac valve and other major cardiothoracic procedures without cardiac catheterization with cc
228	Other cardiothoracic procedures with mcc
233	Coronary bypass with cardiac catheterization or open ablation with mcc
234	Coronary bypass with cardiac catheterization or open ablation without mcc
235	Coronary bypass without cardiac catheterization with mcc
236	Coronary bypass without cardiac catheterization without mcc
266	Endovascular cardiac valve replacement and supplement procedures with mcc
267	Endovascular cardiac valve replacement and supplement procedures without mcc

ICD-10-CM

Arrythmia

Diagnosis Code	Diagnosis Code Label
I47.1X	Supraventricular Tachycardia
I47.10	Supraventricular Tachycardia, Unspecified
I47.19	Other Supraventricular Tachycardia
I48.X	Atrial Fibrillation and Flutter
I48.0	Paroxysmal Atrial Fibrillation
I48.1	Persistent Atrial Fibrillation
I48.19	Other Persistent Atrial Fibrillation
I48.3	Typical Atrial Flutter
I48.4	Atypical Atrial Flutter
I48.9	Unspecified Atrial Fibrillation And Atrial Flutter
I48.91	Unspecified Atrial Fibrillation
I48.92	Unspecified Atrial Flutter
I47.1X	Supraventricular Tachycardia
I47.10	Supraventricular Tachycardia, Unspecified
I47.19	Other Supraventricular Tachycardia
I48.X	Atrial Fibrillation and Flutter
I48.0	Paroxysmal Atrial Fibrillation
I48.1	Persistent Atrial Fibrillation
I48.19	Other Persistent Atrial Fibrillation
I48.3	Typical Atrial Flutter
I48.4	Atypical Atrial Flutter
I48.9	Unspecified Atrial Fibrillation And Atrial Flutter

Heart Failure

Diagnosis Code	Diagnosis Code Label
I09.81	Rheumatic Heart Failure
I11.0	Hypertensive Heart Disease With Heart Failure
I13.0	Hypertensive Heart And Chronic Kidney Disease With Heart Failure And Stage 1 Through Stage 4 Chronic Kidney Disease, Or Unspecified Chronic Kidney Disease
I13.2	Hypertensive Heart And Chronic Kidney Disease With Heart Failure And With Stage 5 Chronic Kidney Disease, Or End Stage Renal Disease
I50.X	Heart Failure
I50.20	Unspecified Systolic (Congestive) Heart Failure
I50.21	Acute Systolic (Congestive) Heart Failure
I50.22	Chronic Systolic (Congestive) Heart Failure
I50.23	Acute On Chronic Systolic (Congestive) Heart Failure
I50.30	Unspecified Diastolic (Congestive) Heart Failure
I50.31	Acute Diastolic (Congestive) Heart Failure
I50.32	Chronic Diastolic (Congestive) Heart Failure
I50.33	Acute On Chronic Diastolic (Congestive) Heart Failure
I50.40	Unspecified Combined Systolic (Congestive) And Diastolic (Congestive) Heart Failure
I50.41	Acute Combined Systolic (Congestive) And Diastolic (Congestive) Heart Failure
I50.42	Chronic Combined Systolic (Congestive) And Diastolic (Congestive) Heart Failure
I50.43	Acute On Chronic Combined Systolic (Congestive) And Diastolic (Congestive) Heart Failure
I50.810	Right Heart Failure, Unspecified
I50.811	Acute Right Heart Failure
I50.812	Chronic Right Heart Failure
I50.813	Acute On Chronic Right Heart Failure
I50.82	Biventricular Heart Failure
I50.84	End Stage Heart Failure
I50.89	Other Heart Failure
I50.9	Heart Failure, Unspecified
I97.13	Postprocedural Heart Failure

Hospital Revenue Codes

Revenue Code	Description
0252	Non-generic drugs
0258	IV solutions
0260	General IV Therapy
0262	Pharmacy Services
0631	Single Source Drug

IMPORTANT SAFETY INFORMATION

Contraindications

RAPIBLYK^TM is contraindicated in patients with:

Severe sinus bradycardia, sick sinus syndrome, heart block greater than first degree
Decompensated heart failure
Cardiogenic shock
Pulmonary hypertension
Hypersensitivity reactions to RAPIBLYK^TM or any of the inactive ingredients

Warning and Precautions

Hypotension: Patients with hemodynamic compromise, hypovolemia, or on interacting medications are at increased risk of hypotension.
Bradycardia: Patients with first-degree atrioventricular block, sinus node dysfunction, or conduction disorders are at increased risk of bradycardia, including sinus pause, heart block, severe bradycardia, and cardiac arrest.
Cardiac Failure: Beta-blockers, like RAPIBLYK^TM, can cause depression of myocardial contractility and may precipitate heart failure and cardiogenic shock.
Reactive Airways Disease: Patients with reactive airways disease should, in general, not receive Beta blockers. Because of its relative beta-1 selectivity and titratability, RAPIBLYK^TM injection may be titrated to the lowest possible effective dose.
Patients with Diabetes Mellitus and Hypoglycemia: beta blockers may prevent early warning signs of hypoglycemia, such as tachycardia, and increase the risk for severe or prolonged hypoglycemia at any time during treatment, especially in patients with diabetes mellitus, patients who are fasting, or children.
Infusion Site Reactions: Infusion site reactions such as pain, swelling and erythema have occurred with the use of RAPIBLYK^TM.
Patients with Prinzmetal’s Angina: beta blockers may exacerbate anginal attacks.
Patients with Pheochromocytoma: Administration of RAPIBLYK without opposing alpha blockade in the setting of pheochromocytoma has been associated with a paradoxical increase in blood pressure from the attenuation of beta receptor-mediated vasodilation in skeletal muscle.
Patients with Peripheral Circulatory Disorders: RAPIBLYK^TM may exacerbate peripheral circulatory disorders, such as Raynaud’s disease or syndrome, and peripheral occlusive vascular disease.
Abrupt Discontinuation of RAPIBLYK Injection: Severe exacerbations of angina, myocardial infarction, and ventricular arrhythmias have been reported in patients with coronary artery disease upon abrupt discontinuation of beta-blocker therapy.
Hyperkalemia: Beta-blockers, including RAPIBLYK^TM, can cause increases in serum potassium and hyperkalemia. The risk is increased in patients with risk factors such as renal impairment.
Patients with Metabolic Acidosis: Beta-blockers have been reported to cause hyperkalemic renal tubular acidosis.
Patients with Hyperthyroidism: Beta-adrenergic blockade may mask certain clinical signs of hyperthyroidism.
Patients at Risk of Severe Acute Hypersensitivity Reactions: may be more reactive to allergen exposure. Patients using beta blockers may be unresponsive to the usual doses of epinephrine used to treat anaphylactic or anaphylactoid reactions.

Adverse Reactions

The most important and common adverse reaction is hypotension, which in clinical trials occurred in 9.9% of patients receiving RAPIBLYK^TMvs. 1% in those receiving placebo.

Please see the full Prescribing Information for RAPIBLYK^TM at